TSE:ATE

Antibe Therapeutics Competitors

C$4.65
-0.23 (-4.71 %)
(As of 04/12/2021 12:00 AM ET)
Add
Compare
Today's Range
C$4.56
Now: C$4.65
C$4.90
50-Day Range
C$4.54
MA: C$5.06
C$6.12
52-Week Range
C$3.05
Now: C$4.65
C$8.90
Volume298,221 shs
Average Volume232,497 shs
Market CapitalizationC$211.61 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Antibe Therapeutics (TSE:ATE) Vs. APS, BU, TH, BLU, NRI, and PLI

Should you be buying ATE stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Antibe Therapeutics, including Aptose Biosciences (APS), Burcon NutraScience (BU), Theratechnologies (TH), BELLUS Health (BLU), Nuvo Pharmaceuticals Inc. (NRI.TO) (NRI), and ProMetic Life Sciences (PLI).

Antibe Therapeutics (TSE:ATE) and Aptose Biosciences (TSE:APS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, analyst recommendations, valuation, risk and profitability.

Valuation & Earnings

This table compares Antibe Therapeutics and Aptose Biosciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Antibe TherapeuticsC$9.33 million22.68C$-35,814,009.00C($0.79)-5.91
Aptose BiosciencesN/AN/AN/AC($0.85)-7.52

Aptose Biosciences has lower revenue, but higher earnings than Antibe Therapeutics. Aptose Biosciences is trading at a lower price-to-earnings ratio than Antibe Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Antibe Therapeutics and Aptose Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Antibe TherapeuticsN/AN/AN/A
Aptose BiosciencesN/AN/AN/A

Analyst Recommendations

This is a breakdown of current recommendations for Antibe Therapeutics and Aptose Biosciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Antibe Therapeutics00203.00
Aptose Biosciences00203.00

Antibe Therapeutics presently has a consensus price target of C$7.75, suggesting a potential upside of 66.67%. Aptose Biosciences has a consensus price target of C$12.00, suggesting a potential upside of 88.68%. Given Aptose Biosciences' higher probable upside, analysts plainly believe Aptose Biosciences is more favorable than Antibe Therapeutics.

Summary

Antibe Therapeutics beats Aptose Biosciences on 3 of the 4 factors compared between the two stocks.

Antibe Therapeutics (TSE:ATE) and Burcon NutraScience (TSE:BU) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, analyst recommendations, valuation, risk and profitability.

Valuation & Earnings

This table compares Antibe Therapeutics and Burcon NutraScience's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Antibe TherapeuticsC$9.33 million22.68C$-35,814,009.00C($0.79)-5.91
Burcon NutraScienceC$12,045.0045,703.54C$107,101.00C$0.005,140.00

Burcon NutraScience has lower revenue, but higher earnings than Antibe Therapeutics. Antibe Therapeutics is trading at a lower price-to-earnings ratio than Burcon NutraScience, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Antibe Therapeutics and Burcon NutraScience's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Antibe TherapeuticsN/AN/AN/A
Burcon NutraScienceN/AN/AN/A

Analyst Recommendations

This is a breakdown of current recommendations for Antibe Therapeutics and Burcon NutraScience, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Antibe Therapeutics00203.00
Burcon NutraScience00103.00

Antibe Therapeutics presently has a consensus price target of C$7.75, suggesting a potential upside of 66.67%. Burcon NutraScience has a consensus price target of C$5.00, suggesting a potential downside of 2.72%. Given Antibe Therapeutics' higher probable upside, analysts plainly believe Antibe Therapeutics is more favorable than Burcon NutraScience.

Summary

Burcon NutraScience beats Antibe Therapeutics on 4 of the 7 factors compared between the two stocks.

Antibe Therapeutics (TSE:ATE) and Theratechnologies (TSE:TH) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, analyst recommendations, valuation, risk and profitability.

Valuation & Earnings

This table compares Antibe Therapeutics and Theratechnologies' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Antibe TherapeuticsC$9.33 million22.68C$-35,814,009.00C($0.79)-5.91
TheratechnologiesC$66.05 million7.06C$-34,627,329.00C($0.37)-13.47

Theratechnologies has higher revenue and earnings than Antibe Therapeutics. Theratechnologies is trading at a lower price-to-earnings ratio than Antibe Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Antibe Therapeutics and Theratechnologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Antibe TherapeuticsN/AN/AN/A
TheratechnologiesN/AN/AN/A

Analyst Recommendations

This is a breakdown of current recommendations for Antibe Therapeutics and Theratechnologies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Antibe Therapeutics00203.00
Theratechnologies02002.00

Antibe Therapeutics presently has a consensus price target of C$7.75, suggesting a potential upside of 66.67%. Theratechnologies has a consensus price target of C$3.75, suggesting a potential downside of 24.55%. Given Antibe Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Antibe Therapeutics is more favorable than Theratechnologies.

Summary

Antibe Therapeutics beats Theratechnologies on 5 of the 8 factors compared between the two stocks.

Antibe Therapeutics (TSE:ATE) and BELLUS Health (TSE:BLU) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, analyst recommendations, valuation, risk and profitability.

Analyst Recommendations

This is a breakdown of current recommendations for Antibe Therapeutics and BELLUS Health, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Antibe Therapeutics00203.00
BELLUS Health01202.67

Antibe Therapeutics presently has a consensus price target of C$7.75, suggesting a potential upside of 66.67%. Given Antibe Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Antibe Therapeutics is more favorable than BELLUS Health.

Profitability

This table compares Antibe Therapeutics and BELLUS Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Antibe TherapeuticsN/AN/AN/A
BELLUS HealthN/AN/AN/A

Valuation & Earnings

This table compares Antibe Therapeutics and BELLUS Health's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Antibe TherapeuticsC$9.33 million22.68C$-35,814,009.00C($0.79)-5.91
BELLUS HealthC$15,000.0029,768.06C$-42,145,306.00C($0.54)-10.59

Antibe Therapeutics has higher revenue and earnings than BELLUS Health. BELLUS Health is trading at a lower price-to-earnings ratio than Antibe Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Antibe Therapeutics beats BELLUS Health on 5 of the 7 factors compared between the two stocks.

Antibe Therapeutics (TSE:ATE) and Nuvo Pharmaceuticals Inc. (NRI.TO) (TSE:NRI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Antibe Therapeutics and Nuvo Pharmaceuticals Inc. (NRI.TO), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Antibe Therapeutics00203.00
Nuvo Pharmaceuticals Inc. (NRI.TO)00103.00

Antibe Therapeutics presently has a consensus price target of C$7.75, suggesting a potential upside of 66.67%. Given Antibe Therapeutics' higher possible upside, analysts clearly believe Antibe Therapeutics is more favorable than Nuvo Pharmaceuticals Inc. (NRI.TO).

Profitability

This table compares Antibe Therapeutics and Nuvo Pharmaceuticals Inc. (NRI.TO)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Antibe TherapeuticsN/AN/AN/A
Nuvo Pharmaceuticals Inc. (NRI.TO)N/AN/AN/A

Valuation & Earnings

This table compares Antibe Therapeutics and Nuvo Pharmaceuticals Inc. (NRI.TO)'s top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Antibe TherapeuticsC$9.33 million22.68C$-35,814,009.00C($0.79)-5.91
Nuvo Pharmaceuticals Inc. (NRI.TO)C$76.09 million5.48C$-6,980,844.00C($0.61)-59.71

Nuvo Pharmaceuticals Inc. (NRI.TO) has higher revenue and earnings than Antibe Therapeutics. Nuvo Pharmaceuticals Inc. (NRI.TO) is trading at a lower price-to-earnings ratio than Antibe Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Antibe Therapeutics beats Nuvo Pharmaceuticals Inc. (NRI.TO) on 4 of the 7 factors compared between the two stocks.

Antibe Therapeutics (TSE:ATE) and ProMetic Life Sciences (TSE:PLI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Antibe Therapeutics and ProMetic Life Sciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Antibe Therapeutics00203.00
ProMetic Life Sciences0000N/A

Antibe Therapeutics presently has a consensus price target of C$7.75, suggesting a potential upside of 66.67%.

Profitability

This table compares Antibe Therapeutics and ProMetic Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Antibe TherapeuticsN/AN/AN/A
ProMetic Life SciencesN/AN/AN/A

Valuation & Earnings

This table compares Antibe Therapeutics and ProMetic Life Sciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Antibe TherapeuticsC$9.33 million22.68C$-35,814,009.00C($0.79)-5.91
ProMetic Life SciencesC$39.91 million0.00C$-1,470,117,780.00C($63.06)N/A

Antibe Therapeutics has higher earnings, but lower revenue than ProMetic Life Sciences. Antibe Therapeutics is trading at a lower price-to-earnings ratio than ProMetic Life Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Antibe Therapeutics beats ProMetic Life Sciences on 3 of the 5 factors compared between the two stocks.


Antibe Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
APS
Aptose Biosciences
1.3$6.36-3.9%C$565.31 millionN/A-7.52
BU
Burcon NutraScience
1.2$5.14-5.4%C$550.50 millionC$12,045.005,140.00Gap Down
Theratechnologies logo
TH
Theratechnologies
0.7$4.97-4.0%C$466.39 millionC$66.05 million-13.47
BLU
BELLUS Health
0.5$5.70-4.4%C$446.52 millionC$15,000.00-10.59
NRI
Nuvo Pharmaceuticals Inc. (NRI.TO)
0.8$36.60-1.8%C$416.80 millionC$76.09 million-59.71
ProMetic Life Sciences logo
PLI
ProMetic Life Sciences
0.5N/AN/AC$315.66 millionC$39.91 million-0.22
NEPT
Neptune Wellness Solutions
1.2$1.64-7.9%C$271.41 millionC$52.78 million-1.21
MDNA
Medicenna Therapeutics
0.5$5.00-1.6%C$264.51 millionN/A-16.18
EMC
Emblem
0.5$1.88-1.6%$248.31 million$5.71 million-9.89
IMV logo
IMV
IMV
1.2$3.55-2.0%C$240.37 millionC$3,000.00-6.14
ONC
Oncolytics Biotech
1.2$4.13-20.8%C$217.94 millionN/A-7.38High Trading Volume
News Coverage
Gap Down
RVX
Resverlogix
0.7$0.91-5.5%C$212.93 millionN/A82.73Upcoming Earnings
News Coverage
Gap Down
FRX
Fennec Pharmaceuticals
0.5$7.51-4.1%C$195.28 millionC$170,000.00-7.84
IPA
ImmunoPrecise Antibodies
0.4$15.29-0.8%C$123.03 millionC$17.18 million-71.45
HBP
Helix BioPharma
0.5$0.83-10.8%C$117.14 millionN/A-15.09
ACST
Acasti Pharma Inc. (ACST.V)
0.8$0.64-6.3%C$88.79 millionC$81,000.0018.82News Coverage
NVH
Novoheart
0.5$0.53-1.9%C$79.23 millionC$423,500.00-13.95
MBX
Microbix Biosystems
0.9$0.62-11.3%C$67.86 millionC$11.64 million-12.16High Trading Volume
PDP
Pediapharm
0.5$0.30-1.7%C$66.36 millionC$11.16 million-4.11
PMN
ProMIS Neurosciences
0.5$0.22-4.7%C$65.78 millionC$1,787.00-10.75
SBM
Sirona Biochem
0.5$0.35-8.6%C$58.80 millionC$123,870.00-26.92Gap Up
COV
Covalon Technologies
0.6$1.41-0.7%C$37.44 millionC$23.84 million-5.92
Emerald Health Therapeutics logo
EMH
Emerald Health Therapeutics
0.5$0.27-9.4%C$34.02 millionC$13.02 million-0.38
IGX
IntelGenx Technologies
0.9$0.66-13.6%C$30.87 millionC$1.54 million-10.15High Trading Volume
News Coverage
QPT
Quest PharmaTech
0.8$0.11-0.0%C$21.76 millionC$38,871.000.17High Trading Volume
Gap Down
CZO
Ceapro
0.6$0.79-8.9%C$21.65 millionC$16.14 million23.94
CTX
Crescita Therapeutics
0.6$0.85-1.2%C$17.55 millionC$15.64 million425.00
KNE
Kane Biotech
0.4$0.16-6.3%C$14.12 millionC$1.34 million-4.57
GSD
Devonian Health Group
0.5$0.27-3.7%C$13.96 millionC$1.59 million-5.63Gap Up
PAS
Pascal Biosciences
0.6$0.09-5.6%C$12.70 millionN/A-4.09
NSP
Naturally Splendid Enterprises
0.6$0.06-0.0%C$11.06 millionC$2.03 million-1.40Gap Down
MPH
Medicure
0.7$1.60-0.0%C$10.80 millionC$12.71 million-1.03Gap Up
BTI
Bioasis Technologies
0.7$0.44-11.4%C$10.16 millionC$4.12 million40.00
HEM
Hemostemix
0.6$0.48-2.1%C$9.07 millionN/A-2.86
ICO
iCo Therapeutics
0.5$0.11-0.0%C$7.69 millionN/A-8.75
IBT
IBEX Technologies
0.7$0.36-1.4%C$6.94 millionC$5.60 million6.67
IOT
Innovotech
0.8$0.15-3.3%C$6.52 millionC$1.04 million75.00
BCT
BriaCell Therapeutics
0.5$4.90-30.6%C$4.48 millionN/A-1.58High Trading Volume
Gap Down
RVV
Revive Therapeutics
0.5$0.08-12.5%C$3.62 millionN/A-3.64High Trading Volume
News Coverage
Gap Down
COT
Cotinga Pharmaceuticals Inc. (COT.V)
0.5$0.04-71.4%C$1.54 millionN/A-0.30Upcoming Earnings
Gap Up
PBS
Pacgen Life Science Co. (PBS.V)
0.6$0.03-16.7%C$1.30 millionC$302,079.00-5.00Gap Down
MFS
Medifocus Inc. (MFS.V)
0.5$0.01-0.0%C$925,000.00C$2.23 million-1.00
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
COM
138267 (COM.TO)
0.5$2.95-2.7%C$0.00N/A0.00
MYM
17031
0.4N/AN/AC$0.00N/A0.00
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
HALO
Halozyme Therapeutics
1.7N/AN/AC$0.00C$267.59 million47.20
LTY
Liberty Biopharma
0.6$2.00-100.0%C$0.00N/A-12.66Gap Down
MMJ
Matica Enterprises
0.5N/AN/AC$0.00N/A0.00High Trading Volume
This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.